List of Excipients in Branded Drug OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE 20/5/12.5 MG

Generic Drugs Containing OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE 20/5/12.5 MG

Company	Ingredient	NDC	Excipient
Torrent Pharmaceuticals Limited	olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet 20/5/12.5 mg	13668-397	CROSCARMELLOSE SODIUM
Torrent Pharmaceuticals Limited	olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet 20/5/12.5 mg	13668-397	FERRIC OXIDE RED
Torrent Pharmaceuticals Limited	olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet 20/5/12.5 mg	13668-397	FERRIC OXIDE YELLOW

What are the Most Frequently-Used Excipients in OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE 20/5/12.5 MG?

# Of NDCs	Excipient
1	CROSCARMELLOSE SODIUM
1	FERRIC OXIDE RED
1	FERRIC OXIDE YELLOW

Olmesartan Medoxomil/Amlodipine/Hydrochlorothiazide 20/5/12.5 mg: Excipient Strategy and Commercial Opportunities

Last updated: August 5, 2026

Olmesartan medoxomil/amlodipine/hydrochlorothiazide 20/5/12.5 mg is a fixed-dose, immediate-release antihypertensive tablet combining an angiotensin II receptor blocker, a calcium-channel blocker, and a thiazide diuretic. The product was originally commercialized in the United States as Tribenzor by Daiichi Sankyo and was approved by the FDA in 2010.[1] Its commercial opportunity now centers on generic substitution, differentiated excipient systems, manufacturing efficiency, global registration, and lifecycle extensions rather than primary-drug exclusivity.

The formulation challenge is disproportionate to the tablet’s small dose: the product must deliver 20 mg of olmesartan medoxomil, 5 mg of amlodipine, and only 12.5 mg of hydrochlorothiazide with consistent content uniformity, dissolution, stability, and tablet appearance.

What is the regulatory status of olmesartan/amlodipine/hydrochlorothiazide 20/5/12.5 mg?

The product is an FDA-approved immediate-release combination tablet for hypertension in patients requiring treatment with all three components.[1]

Attribute	Product information
Active ingredients	Olmesartan medoxomil, amlodipine, hydrochlorothiazide
Strength	20 mg/5 mg/12.5 mg
Dosage form	Film-coated tablet
Administration	Once daily
Reference product	Tribenzor
Original sponsor	Daiichi Sankyo
FDA approval	2010
Therapeutic class	Antihypertensive fixed-dose combination
Primary regulatory pathway for competitors	ANDA, subject to reference-product requirements
Biosimilar pathway	Not applicable; this is a small-molecule product

The fixed-dose product is intended for patients whose blood pressure is not adequately controlled with two agents or who are already receiving the three active ingredients separately.[1] Generic products must demonstrate pharmaceutical equivalence and bioequivalence to the applicable reference listed drug.

What excipients are used in the reference formulation?

The US labeling for Tribenzor identifies a conventional tablet platform using fillers, binders, disintegrant functionality, lubricants, glidants, and film-coating materials.[1] Public labeling identifies inactive ingredients including microcrystalline cellulose, lactose monohydrate, low-substituted hydroxypropyl cellulose, hydroxypropyl cellulose, magnesium stearate, talc, titanium dioxide, and iron oxide coloring agents.[1]

The precise excipient system can differ among generic manufacturers. A proposed generic does not need to duplicate the reference product’s excipients. It must achieve equivalent product performance and satisfy quality, stability, safety, and regulatory requirements.

Likely functional roles of the principal excipients

Excipient	Formulation function	Strategic relevance
Microcrystalline cellulose	Diluent and dry-binder	Supports direct compression and tablet strength
Lactose monohydrate	Diluent	Adds bulk and supports compactability
Low-substituted hydroxypropyl cellulose	Disintegrant	Promotes tablet breakup and dissolution
Hydroxypropyl cellulose	Binder	Controls granule or tablet cohesion
Magnesium stearate	Lubricant	Reduces ejection force; excessive levels can slow dissolution
Talc	Glidant or coating aid	Supports powder flow and film-coat performance
Titanium dioxide	Opacifier and colorant	Controls appearance and light protection
Iron oxides	Colorants	Supports strength differentiation and product identification

The most important development issue is not excipient novelty. It is the interaction between excipients, blend uniformity, and dissolution across all three active ingredients.

How should an excipient strategy address the 20/5/12.5 mg dose combination?

A robust strategy should prioritize content uniformity, dissolution control, moisture protection, and process robustness.

Content uniformity and low-dose distribution

Amlodipine and hydrochlorothiazide represent relatively small fractions of total tablet mass. Segregation risk can arise from differences in particle size, density, morphology, and electrostatic behavior between the active ingredients and excipients.

Recommended controls include:

• Particle-size engineering for all three active ingredients.
• Geometric dilution of amlodipine and hydrochlorothiazide.
• Ordered mixing or carrier-based blending where justified.
• Narrow control of bulk density and flow properties.
• In-process blend uniformity testing.
• Avoidance of excessive lubricant mixing time.
• Use of a common granulation step if direct blending cannot maintain uniformity.

A high-functionality microcrystalline cellulose or co-processed filler can reduce dependence on several individual excipients, but the choice must be validated against dissolution and compression behavior.

Dissolution management

The formulation must avoid a dissolution profile in which one active is released rapidly while another is retarded by hydrophobic lubrication or excessive tablet hardness. Magnesium stearate concentration and mixing time require particular control because over-lubrication can reduce wetting and slow release.

Disintegrant selection should be evaluated against:

• Tablet hardness.
• Disintegration time.
• Dissolution in multiple media.
• Stability after humidity exposure.
• Compression speed and dwell time.

A formulation that performs well in a single dissolution medium but loses release after accelerated aging is commercially weak. Comparative dissolution should cover pH conditions relevant to the reference product and include discriminatory methods for each active ingredient.

Moisture and chemical stability

Olmesartan medoxomil is susceptible to hydrolytic degradation under unfavorable moisture conditions. The formulation should therefore control water activity through excipient selection, granulation conditions, packaging, and coating design.

A practical strategy is:

1. Use low-moisture or controlled-moisture excipients.
2. Avoid unnecessary aqueous processing unless stability data support it.
3. Evaluate hydroxypropyl cellulose and lactose grades for water contribution.
4. Use a protective film coat where it improves handling and stability.
5. Select high-barrier blister or bottle packaging based on stability results.
6. Monitor related substances for all three actives during accelerated and long-term studies.

Packaging can be a larger commercial differentiator than a novel excipient. A lower-cost bottle may be attractive only if it matches the shelf life achieved by a higher-barrier blister.

What formulations are protected by patents or regulatory exclusivity?

The original product’s primary commercial protection was based on the approved product, formulation and combination patent estate, regulatory exclusivity, and manufacturing know-how. The key US exclusivity period has expired, and generic versions of olmesartan/amlodipine/hydrochlorothiazide products have entered the market.

Patent and exclusivity position

Protection category	Current commercial implication
New chemical entity exclusivity	Expired
Original combination-product exclusivity	Expired
Original formulation protection	Historical barrier; no longer a reliable block to ordinary generic entry
Method-of-use patents	Potentially relevant only if unexpired and listed or enforceable for a specific use
Manufacturing know-how	May remain valuable but is difficult to use as a generic-entry barrier
FDA approval requirement	Continues to govern ANDA approval and product quality
Biosimilar protection	Not applicable

The former composition and combination patent estate should be reviewed in the current USPTO and FDA Orange Book records before relying on any specific patent number or expiration date. Patent status can differ by jurisdiction, patent family, terminal disclaimer, pediatric extension, and litigation outcome.

When does olmesartan/amlodipine/hydrochlorothiazide lose exclusivity?

The product lost meaningful US market exclusivity after expiration of its original regulatory and patent protections. Generic entry is therefore commercially established rather than prospective.

The principal business question is no longer whether generic entry is legally possible. It is whether a new entrant can obtain acceptable pricing and distribution in a market with multiple suppliers.

Generic launch timing may still be affected by:

• ANDA review and approval.
• Paragraph IV litigation for any subsequently listed patent.
• Paragraph III certification for patents awaiting expiration.
• Manufacturing-site readiness.
• FDA inspection outcomes.
• Supply commitments to wholesalers and pharmacies.
• State substitution and formulary practices.
• Shortage or discontinuation events involving existing suppliers.

What is the Orange Book and Paragraph IV status?

The Orange Book identifies approved drug products, therapeutic-equivalence information, and certain patent and exclusivity data.[2] For a generic applicant, the relevant ANDA certification may be Paragraph I, II, III, or IV, depending on listed patents and their status.

A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed. It can trigger patent litigation and a potential 30-month stay of ANDA approval under the Hatch-Waxman framework.[3]

For this mature three-drug combination, the practical risk from historical Paragraph IV litigation is lower than the risk associated with manufacturing, pricing, and product availability. A new applicant still must perform a current Orange Book review because later-listed patents, approved labeling changes, or patent corrections can alter the approval pathway.

How strong is the patent estate for this product?

The patent estate is weak as a barrier to conventional generic entry but can remain relevant for differentiated products.

Patent strength by claim type

Claim type	Generic-entry barrier	Commercial value today
Basic combination of three approved actives	Low	Limited
Specific strength, including 20/5/12.5 mg	Low to moderate	Limited unless tied to a valid formulation claim
Immediate-release tablet	Low	Limited
Novel excipient system	Moderate if technically non-obvious	Potentially useful
Taste-masking or swallowability system	Moderate	Relevant for patient-centric products
Modified-release delivery	Higher, but clinically and regulatorily complex	Selective opportunity
Manufacturing process	Moderate if difficult to design around	Potentially valuable
New method of use	Variable	Requires a defensible clinical or label strategy

A new patent portfolio should focus on measurable technical advantages rather than routine substitutions of lactose, cellulose, starch, or standard superdisintegrants. Stronger candidates include reduced tablet mass, improved moisture stability, lower impurity formation, enhanced content uniformity, simplified manufacturing, or a clinically relevant adherence benefit.

What commercial opportunities exist for excipient innovation?

1. Low-cost, high-throughput generic tablets

The largest opportunity is a cost-optimized conventional tablet. A direct-compression platform using a co-processed filler, controlled particle-size actives, and a low-level superdisintegrant can reduce processing steps and improve plant throughput.

The commercial value depends on:

• Yield.
• Compression speed.
• Tablet rejection rate.
• Stability shelf life.
• Packaging cost.
• Supplier redundancy.
• API availability.

A formulation that eliminates wet granulation may have a meaningful cost advantage if it maintains blend uniformity and dissolution.

2. Smaller tablets and improved swallowability

Three active ingredients create a substantial tablet burden. A smaller tablet could improve adherence, particularly among older patients taking multiple medicines.

Potential approaches include:

• Higher-density excipient systems.
• More efficient compaction.
• Reduced coating weight.
• Co-processed excipients.
• Granule engineering.
• Orally disintegrating or rapidly dispersing formats, subject to bioequivalence and stability feasibility.

A smaller tablet may support a 505(b)(2) or other lifecycle strategy only if the product has a defensible clinical, administration, or adherence advantage. Size reduction alone is usually insufficient for strong premium pricing.

3. Moisture-protective formulation and packaging

A formulation that reduces olmesartan medoxomil degradation can support longer shelf life, hot-climate distribution, and lower-cost packaging. This opportunity is particularly relevant in emerging markets where storage conditions are less controlled.

Commercial differentiation could come from:

• A low-moisture excipient platform.
• High-barrier blister packaging.
• Unit-dose packaging.
• Desiccant-integrated bottles.
• Stability data supporting broader climatic zones.

4. Patient-centric presentations

The product is administered once daily, which already supports adherence. Further opportunities include:

• Calendar blister packs.
• Dose-specific color coding.
• Easy-open packaging for older adults.
• Alternative tablet sizes.
• Combination packs for patients transitioning from separate components.

These opportunities are more likely to produce commercial value through contracting, pharmacy preference, or adherence programs than through broad patent exclusivity.

5. Geographic expansion

The active ingredients are widely used globally, and the triple combination has a clear rationale in markets with high rates of uncontrolled hypertension. Opportunities are strongest where:

• Generic competition is fragmented.
• Fixed-dose combinations are included in reimbursement schedules.
• Local manufacturing receives procurement preference.
• Hypertension treatment guidelines support multi-drug therapy.
• Patients face adherence problems with separate tablets.

Registration requirements, reference-product selection, bioequivalence standards, and local patent status differ by country. The US market is mature and price competitive; selected emerging markets may offer better margin potential but higher regulatory and supply-chain complexity.

How does this product compare with competing antihypertensive combinations?

Product category	Competitive position
Olmesartan/amlodipine	Two-drug regimen; lower tablet complexity
Olmesartan/hydrochlorothiazide	Two-drug regimen; useful when calcium-channel blockade is not required
Amlodipine/valsartan/hydrochlorothiazide	Direct triple-combination competitor with a different ARB
Amlodipine/valsartan	Broadly established dual combination
Amlodipine/benazepril or lisinopril/HCTZ	Older, lower-cost alternatives
Separate three-tablet therapy	More flexible dosing but higher pill burden

Olmesartan/amlodipine/hydrochlorothiazide offers regimen simplification but removes individual dose flexibility. This limits use in patients who require different titration of the three components. The strongest commercial positioning is therefore a once-daily maintenance product for patients already stabilized on matching doses.

What generic launch risks exist?

The main risks are commercial and operational.

Pricing pressure

The product contains three widely available generic actives. API costs are manageable, but gross margin can contract rapidly after multiple ANDA approvals. A new entrant needs a clear supply, cost, or channel advantage.

Bioequivalence complexity

A three-active product requires analytical methods capable of measuring all components and relevant degradants. Variability in low-dose hydrochlorothiazide and amlodipine can complicate validation and batch release.

Manufacturing complexity

Potential failure points include:

• Segregation during blending.
• Inconsistent lubrication.
• Tablet capping or lamination.
• Coating color variation.
• Moisture-driven impurity growth.
• Dissolution drift after scale-up.
• API particle-size changes between suppliers.

Substitution and channel access

Large wholesalers and pharmacy chains may prioritize suppliers with reliable allocation, competitive pricing, and low back-order rates. A technically superior formulation has limited value if it cannot maintain service levels.

What litigation and settlement issues affect this product?

Historical Hatch-Waxman litigation may have affected the timing of generic entry, but the original product is now a mature generic category. Any current entrant should review:

• Active Orange Book-listed patents.
• FDA litigation-stay records.
• District court and Federal Circuit decisions.
• Authorized-generic arrangements.
• Supply or licensing agreements.
• Product-specific settlement restrictions.
• Patent assignments and terminal disclaimers.

No biosimilar litigation framework applies because all three active ingredients are chemically synthesized small molecules. Competitive disputes are more likely to involve formulation patents, labeling, trade dress, supply agreements, or manufacturing methods than biologic interchangeability.

What is the revenue exposure and market opportunity?

Revenue exposure is concentrated in the mature generic market. The originator’s historical sales base is less important than the size of the treated hypertension population and the proportion receiving three-drug therapy.

A commercial forecast should model:

1. Total prescriptions for each component.
2. Conversion from separate tablets to fixed-dose therapy.
3. Reimbursement coverage.
4. Number of approved suppliers.
5. Average selling price erosion.
6. Pharmacy substitution rates.
7. Shortage-driven share gains.
8. Geographic mix.
9. Packaging and channel costs.
10. Probability of formulation differentiation.

The highest-value opportunity is unlikely to be an undifferentiated US generic. Better returns may come from a combination of low-cost manufacturing, selected international markets, contract manufacturing, hospital procurement, or a protected patient-centric formulation.

Key Takeaways

• Olmesartan medoxomil/amlodipine/hydrochlorothiazide 20/5/12.5 mg is a mature, FDA-approved fixed-dose antihypertensive combination.
• The formulation’s main technical risks are low-dose content uniformity, dissolution balance, lubrication effects, and moisture-related stability.
• Conventional excipients such as microcrystalline cellulose, lactose, hydroxypropyl cellulose, magnesium stearate, talc, titanium dioxide, and iron oxides are suitable starting points.
• Generic entry is established, and the original exclusivity barrier is no longer the principal commercial issue.
• The strongest formulation opportunities are smaller tablets, improved moisture stability, lower-cost processing, and patient-centric packaging.
• A new patent estate should claim measurable technical improvements rather than routine excipient substitutions.
• US commercial returns are likely to be constrained by price erosion and supplier density.
• Emerging markets, contract manufacturing, and differentiated packaging may offer better opportunities than an undifferentiated US launch.

FAQs

Can a generic manufacturer use different excipients from Tribenzor?

Yes. A generic manufacturer may use different inactive ingredients if the product meets applicable pharmaceutical-equivalence, bioequivalence, quality, stability, and labeling requirements.

Is hydrochlorothiazide the main formulation challenge in the 20/5/12.5 mg tablet?

It is one of the main challenges because the 12.5 mg dose is relatively small and must remain uniformly distributed throughout the blend and finished tablets. Amlodipine also requires close control because it is present at 5 mg.

Would an orally disintegrating version create meaningful market exclusivity?

Not automatically. An orally disintegrating version could support a differentiated regulatory or patent strategy only if it provides a defensible technical or clinical advantage and satisfies the applicable FDA pathway.

Does the product have biosimilar competition?

No. Olmesartan medoxomil, amlodipine, and hydrochlorothiazide are small-molecule active ingredients. Competitors generally enter through generic-drug pathways rather than biosimilar approval.

Which formulation attribute is most likely to support premium pricing?

Improved adherence through smaller tablet size, easier administration, or packaging is more commercially credible than a routine change in filler or lubricant. Premium pricing still requires reimbursement or channel acceptance.

References

1. U.S. Food and Drug Administration. (2010). Tribenzor (olmesartan medoxomil, amlodipine, and hydrochlorothiazide) prescribing information. Daiichi Sankyo, Inc.
2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Refuse-to-receive standards.
4. U.S. Food and Drug Administration. (2024). Guidance for industry: Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA.